Janet MJ Hammond sold $54k of AVIR
Chief Development Officer at Atea Pharmaceuticals, Inc.. 14,029 shares at an average of $3.84, traded Feb 1, 2024, filed Feb 2, 2024.
Score components
- +15RoleOfficer
- +7Trade size$54k at market
- +10Share of holdings soldSold 28% of holdings
- +15Cluster6 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-010967, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 31, 2024 | MOption exercise Common Stock | +46,800 | - | - | 49,391 | Feb 2, 2024 |
| Feb 1, 2024 | SOpen-market sale Common Stock10b5-1 | -14,029 | $3.84 | $54k | 35,362 | Feb 2, 2024 |
| Jan 31, 2024 | MOption exercise Restricted Stock Unitsderivative | -46,800 | $0.00 | $0 | 93,600 | Feb 2, 2024 |
| Jan 31, 2024 | AGrant or award Stock Option (Right to Buy)derivative | +225,200 | $0.00 | $0 | 225,200 | Feb 2, 2024 |
Related signals
Other insiders at Atea Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 31Weak | AVIRbuy Atea Pharmaceuticals, Inc. | Polly A. Murphy director | $25k 6,100 shares | +7% | |
| 41Moderate | AVIRbuy Atea Pharmaceuticals, Inc. | Polly A. Murphy director | $25k 6,100 shares | +7% | |
| 27Weak | AVIRbuy Atea Pharmaceuticals, Inc. | Franklin M Berger director | $81k 25,000 shares | +6% | |
| 50Moderate | AVIRsell Atea Pharmaceuticals, Inc. | Franklin M Berger director | $1.0M 359,606 shares | -44% | |
| 18Weak | Atea Pharmaceuticals, Inc. | Jean-Pierre Sommadossi President, CEO, and Chairman | $234k 57,969 shares | -1% | |
| 27Weak | AVIRsell Atea Pharmaceuticals, Inc. | Bruce Polsky director | $61k 17,544 shares | -21% | |
| 5Weak | Atea Pharmaceuticals, Inc. | Jean-Pierre Sommadossi President, CEO, and Chairman | $4,024 1,006 shares | -0% | |
| 11Weak | Atea Pharmaceuticals, Inc. | John Vavricka Chief Commercial Officer | $45k 11,819 shares | -35% | |
| 12Weak | Atea Pharmaceuticals, Inc. | Wayne Foster EVP, Chief Accounting Officer | $48k 12,477 shares | -37% | |
| 12Weak | Atea Pharmaceuticals, Inc. | Maria Arantxa Horga Chief Medical Officer | $61k 15,870 shares | -38% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.